scholarly journals Mark Josephson and the ICD: A Personal Perspective

2017 ◽  
Vol 6 (1) ◽  
pp. 19
Author(s):  
Charles D Swerdlow ◽  
Keyword(s):  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Personal Perspective ◽  
Early Adopter ◽  
Clinical Tool ◽  
Cardioverter Defibrillator ◽  
Life Saving ◽  
Ambulatory Patients ◽  
Intellectual Integrity ◽  
Unique Therapy

Mark Josephson dedicated his career to the prevention of premature sudden cardiac death (SCD). Toward that goal, he was an early adopter of the implantable cardioverter defibrillator (ICD) and indefatigable advocate for better ICD technology,1 both as a clinical tool and as living laboratory to study SCD in ambulatory patients. With characteristic intellectual integrity and analytical rigour, he sought an honest and balanced appraisal of the life-saving benefits and serious complications of this unique therapy.

scholarly journals INAPPROPRIATE S-ICD PATIENT RECEIVES FALSE POSITIVE SHOCKS

2020 ◽  
Vol 50 (2) ◽  
pp. 69-72
Author(s):  
David Korpas
Keyword(s):  
Sudden Cardiac Death ◽  
False Positive ◽  
Cardiac Death ◽  
Individual Variability ◽  
Double Counting ◽  
Inappropriate Therapy ◽  
Cardioverter Defibrillator ◽  
Patient Screening ◽  
Life Saving ◽  
Patients At Risk

Subcutaneous implantable cardioverter defibrillator (S-ICD) protects the patients at risk for sudden cardiac death while leaving the heart and vasculature untouched. It provides life-saving therapy, but may also deliver inappropriate therapy. Presented case demonstrates a possibility of S-ICD therapy induction due to double-counting. It was original caused by lack of suitable sensing vectors and the solution was possible just particularly. As the inter-individual variability of subcutaneous cardiac signal is considerable, the patient screening should be necessary for identification of such patients, which have an unsuitable subcutaneous sensing signals.

scholarly journals Implantable cardioverter defibrillator to prevent sudden cardiac death in a patient with systemic sclerosis: A clinical case

2012 ◽  
Vol 5 (3) ◽  
pp. e166-e170 ◽  
Author(s):  
Fabio Marsico ◽  
Gianluigi Savarese ◽  
Celestino Sardu ◽  
Cristoforo D’Ascia ◽  
Donatella Ruggiero ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Sudden Cardiac Death ◽  
Implantable Cardioverter Defibrillator ◽  
Cardiac Death ◽  
Clinical Case ◽  
Cardioverter Defibrillator

scholarly journals LEFT VENTRICULAR LEAD IMPLANTATION FOR DETECTION OF VENTRICULAR ARRHYTHMIAS IN PATIENT WITH IMPLANTABLE CARDIOVERTER DEFIBRILLATOR AND LOW R WAVE IN RIGHT VENTRICLE

2021 ◽  
pp. 17
Author(s):  
Keyword(s):  
Sudden Cardiac Death ◽  
Right Ventricle ◽  
Implantable Cardioverter Defibrillator ◽  
Cardiac Death ◽  
Ventricular Arrhythmias ◽  
Systolic Function ◽  
Left Ventricular ◽  
Icd Implantation ◽  
Cardioverter Defibrillator ◽  
Ventricular Lead

Dilated cardiomyopathy (DCM) is a disease characterised as left ventricular (LV) or biventricular dilatation with impaired systolic function. Regardless of underlying cause patients with DCM have a propensity to ventricular arrhythmias and sudden cardiac death. Implantable Cardioverter Defibrillator (ICD) implantation for these patients results in significant reduction of sudden cardiac death [1-3]. ICD devices may be limited by right ventricle (RV) sensing dysfunction with low RV sensing amplitude. We present a clinical case of patient with DCM, implanted ICD and low R wave sensing on RV lead.

Secondary prevention of sudden cardiac death in ischaemic cardiomyopathy

ESC CardioMed ◽  
2018 ◽  
pp. 2337-2341
Author(s):  
Jens Cosedis Nielsen ◽  
Jens Kristensen
Keyword(s):  
Heart Failure ◽  
Cardiac Arrest ◽  
Heart Disease ◽  
High Risk ◽  
Sudden Cardiac Death ◽  
Secondary Prevention ◽  
Cardiac Death ◽  
Cardioverter Defibrillator ◽  
Ischaemic Cardiomyopathy ◽  
Life Threatening

The most common reason for sudden cardiac death is ischaemic heart disease. Patients who survive cardiac arrest are at particularly high risk of recurrent ventricular arrhythmia and sudden cardiac death, and are candidates for secondary prevention defined as ‘therapies to reduce the risk of sudden cardiac death in patients who have already experienced an aborted cardiac arrest or life-threatening arrhythmias’. The mainstay therapy for secondary prevention of sudden cardiac death is implantation of an implantable cardioverter defibrillator. Furthermore, revascularization and optimal medical therapy for heart failure and concurrent cardiovascular diseases should be ensured.

Tachycardias

2014 ◽  
pp. 243-260 ◽  
Keyword(s):  
Atrial Fibrillation ◽  
Sudden Cardiac Death ◽  
General Population ◽  
Implantable Cardioverter Defibrillator ◽  
Cardiac Death ◽  
Cardioverter Defibrillator ◽  
Priority Areas ◽  
Diagnosis And Management ◽  
Broad Complex

This chapter looks at the diagnosis and management of tachycardias, including both narrow complex tachycardias and broad complex tachycardias. Atrial fibrillation (AF) is the most common sustained arrhythmia, affecting 1–2% of the general population (5–15% of those over 80 years). There have been a number of developments in arrhythmia care over the last few years in particular in relation to AF and there are now more specialist arrhythmia nurses and nurse-led arrhythmia services than before. AF, arrhythmias, and sudden cardiac death are priority areas of NHS improvement. Recent guidelines for the management of tachycardias are discussed including pharmacological measure, cardioversion, and implantable cardioverter-defibrillator (ICD) insertion.

Ventricular tachycardia and sudden cardiac death might complicate the long-term outcome by patients after tetralogy of Fallot repair

2008 ◽  
Vol 149 (23) ◽  
pp. 1067-1069
Author(s):  
Attila Mihálcz ◽  
Csaba Földesi ◽  
Tamás Szili-Török
Keyword(s):  
Ventricular Tachycardia ◽  
Sudden Cardiac Death ◽  
Tetralogy Of Fallot ◽  
Cardiac Death ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Cardioverter Defibrillator ◽  
Tetralogy Of Fallot Repair

A Fallot-tetralógia miatti műtétet követően a hosszú távú túlélést befolyásoló tényezők közé tartozik a kamrai tachycardia és a hirtelen szívhalál. E betegek gondozásában érdemi segítséget jelent az implantálható cardioverter defibrillátor rendszer. A végleges pacemaker és/vagy implantálható cardioverter defibrillátor implantációját követően ritka, ám potenciálisan letális kimenetelű fertőzéses szövődmény az endocarditis. Ez esetben a leghatékonyabb kezelési mód a kombinált terápia, amely a beültetett készülék + elektródák teljes körű eltávolításából és agresszív antibiotikus kezelésből áll. Célkitűzés: Ilyen esetekben a tervezett reimplantáció különös óvatosságot igényel a nagyobb recidívaarány miatt, amelynek rizikója fokozottabb pacemakerdependencia esetén. Célunk olyan módszer alkalmazása volt, amelynek segítségével a recidíva kockázata minimálisra csökkenthető. Módszer: Esetünkben a korábban Fallot-tetralógia miatt többször műtött, pacemaker-, majd implantálható cardioverter defibrillátor beültetéseken átesett betegnél recidív endocarditis miatt készülék- és elektródaeltávolítást végeztünk, standard antibiotikus terápia alkalmazásával. A reimplantációt minithoracotomián keresztül végeztük. Az így elhelyezett sokkelektróda elégtelen működése miatt egy másik sokkelektródát szubkután vezettünk a hátsó mellkasfali régióba; rendszerünk az indukált kamrafibrillációt sikerrel szüntette meg. Megbeszélés: Esetismertetésünk demonstrálja a szubkután defibrillátorrendszer alkalmazhatóságát és előnyeit speciális körülmények fennállásakor. Felhívjuk a figyelmet arra a tényre, hogy ezt a technikát gyakrabban is lehetne alkalmazni olyan esetekben, amelyekben a transzvénás implantáció nem optimális.

Sign in / Sign up

Export Citation Format

Share Document